Latest News
& Press Releases

In addition to laying off employees, including a member of its management team, Lisata Therapeutics is also suing Kuva Labs, alleging the company breached a merger agreement.

Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be more mixed.

The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis.

Latigo Biotherapeutics is looking to raise up to $285.2 million for a non-opioid analgesic, while BlossomHill Therapeutics is eyeing up to $129.1 million in proceeds for its oncology pipeline.

Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed.

Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said on the company’s second quarter earnings call.

New preclinical findings demonstrate successful oral delivery of single-, dual- and triple-agonist peptide therapeutics using Toralgen’s proprietary nanoparticle platform, supported by specialized bioanalytical expertise from Veloxity Labs.

Protect Clinical Assets. Preserve Enterprise Value. ClinPro Trials™ today announced the availability of its Independent Executive Compliance Intelligence™ service for investors seeking objective visibility into clinical trial compliance, inspection readiness and regulatory exposure across their clinical investment portfolios. As The Compliance CRO™, ClinPro Trials provides independent executive assessments designed to help protect clinical assets and preserve enterprise value. Every investor expects scientific risk. Few expect compliance failure. Fewer expect to discover it after years of investment and hundreds of millions of dollars—during a pre-approval inspection. A pre-approval inspection often reveals compliance deficiencies that could have been identified much earlier. Not because the science failed. But because compliance drifted during trial execution. Every milestone appeared to have been achieved. Every executive update suggested progress. But one critical question remained unanswered: Do we truly understand the compliance risk, inspection readiness and regulatory exposure of the clinical asset we are funding? ClinPro Trials™ was established to answer that question.

Highlight: Voiant expands into obesity and metabolic disease research, helping sponsors move beyond traditional weight-loss measures with advanced body composition and metabolic imaging endpoints.